1. Cardiovascular Risk Scores among Asymptomatic Adults with Haemophilia.
- Author
-
Camelo RM, Caram-Deelder C, Duarte BP, Moura MCB, Costa NCM, Costa IM, Vanderlei AM, Guimarães TMR, Gouw S, Rezende SM, and Bom JV
- Subjects
- Adult, Male, Humans, Middle Aged, Cross-Sectional Studies, Risk Factors, Heart Disease Risk Factors, Hemophilia A complications, Hemophilia A epidemiology, Cardiovascular Diseases epidemiology, Cardiovascular Diseases etiology
- Abstract
Background: The mortality rate of Brazilian people with haemophilia (PwH) is decreasing, but the relative incidence of deaths associated with cardiovascular disease (CVD) is increasing., Objectives: We aimed to describe the CVD risk score of PwH according to Pooled Cohort Equations Risk (PCER) Calculator tool and its treatment recommendations. We also compared the PCER estimates with the respective Framingham Risk Score (FRS)., Methods: This cross-sectional study included male PwH ≥ 40 years treated at the Comprehensive Haemophilia Treatment Centre of Pernambuco (Recife/Brazil). PwH with a previous CVD event or a low-density lipid cholesterol ≥ 5.0 mmol/L were excluded. Interviews, medical file reviews, and blood tests were performed. The PCER tool was used to estimate the CVD risk and compare it with the respective FRS. A p-value < 0.05 was accepted as statistically significant., Results: Thirty PwH were included. Median age was 51.5 [interquartile range-IQR; 46.0-59.5] years. The prevalence of obesity, systemic arterial hypertension, diabetes mellitus, hypertriglyceridaemia, hypercholesterolaemia, and hypoHDLaemia were 20%, 67%, 24%, 14%, 47%, and 23%, respectively. The median PCER score was 6.9% [IQR; 3.1-13.2], with 50% having a high risk (PCER ≥ 7.5%). Statin use was suggested for 54% of PwH. Blood pressure was poorly controlled in 47% of PwH. The agreement between PCER and FRS was 80% (κ = 0.60; p = 0.001)., Conclusions: Half of the male people with haemophilia aged 40 years or older had a 10-year high risk of developing CVD with strong recommendations to improve control of dyslipidaemia and blood pressure.
- Published
- 2023
- Full Text
- View/download PDF